Comparing accuracy of tomosynthesis plus digital mammography or synthetic 2D mammography in breast cancer screening: baseline results of the MAITA RCT consortium
Paolo Giorgi Rossi,Pamela Mancuso,Pierpaolo Pattacini,Cinzia Campari,Andrea Nitrosi,Valentina Iotti,Antonio Ponti,Alfonso Frigerio,L. Correale,Emilia Riggi,Livia Giordano,Nereo Segnan,Giovanni Di Leo,Veronica Magni,Francesco Sardanelli,Francesca Fornasa,Giovanna Romanucci,Stefania Montemezzi,Patrizia Falini,Noemi Auzzi,Marco Zappa,Marta Ottone,Paola Mantellini,Stephen W. Duffy,Paola Armaroli,MAITA Working Group
DOI: https://doi.org/10.2139/ssrn.4508422
IF: 10.002
2024-01-19
European Journal of Cancer
Abstract:Aim The analyses here reported aim to compare the screening performance of digital tomosynthesis (DBT) versus mammography (DM). Methods MAITA is a consortium of four Italian trials, REtomo, Proteus, Impeto, and MAITA trial. The trials adopted a two-arm randomized design comparing DBT plus DM (REtomo and Proteus) or synthetic-2D (Impeto and MAITA trial) versus DM; multiple vendors were included. Women aged 45 to 69 years were individually randomized to one round of DBT or DM. Findings From March 2014 to February 2022, 50,856 and 63,295 women were randomized to the DBT and DM arm, respectively. In the DBT arm, 6,656 women were screened with DBT plus synthetic-2D. Recall was higher in the DBT arm (5·84% versus 4·96%), with differences between centres. With DBT, 0·8/1,000 (95% CI 0·3 to 1·3) more women received surgical treatment for a benign lesion. The detection rate was 51% higher with DBT, ie. 2·6/1,000 (95% CI 1·7 to 3·6) more cancers detected, with a similar relative increase for invasive cancers and ductal carcinoma in situ. The results were similar below and over the age of 50, at first and subsequent rounds, and with DBT plus DM and DBT plus synthetic-2D. No learning curve was appreciable. Detection of cancers >= 20 mm, with 2 or more positive lymph nodes, grade III, HER2-positive, or triple-negative was similar in the two arms. Interpretation Results from MAITA confirm that DBT is superior to DM for the detection of cancers, with a possible increase in recall rate. DBT performance in screening should be assessed locally while waiting for long-term follow-up results on the impact of advanced cancer incidence.
oncology